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Phyllis Greenberger*:
I am going to start by giving a little bit of the history
of the Society for Women's Health Research (Society)
and how we got into the issue of clinical trials and
sex based biology. Ihen I would like to talk about
some of the barriers that we still face and some of the
solutions that my organization thinks we can offer. For
those of you who are not familiar with us, we are the
only national non-profit organization whose mission
is to improve the health of women through research,
education, and advocacy. We were founded in 1990.
We focused our initial work on the inclusion of women
and minorities in clinical trials and also on conditions
that differently, disproportionately, or exclusively
aftected women. At that point in time women's health
was exclusively defined as reproductive issues. the
National Institute of Child and IHuman Development
was the only organization doing research. That
research focused on maternal issues. At other institutes
and in private industry there was minimal or no
focus on the other conditions that affected women
differently or disproportionately. A few years after
that initial focus, we started getting into the issue
of biological differences between men and women.
Since our inception we hav e been very influential at
HH14S, including at the FDA, NilH, and various other
agencies. We have also influenced private industry,
which does the bulk of pharmaceutical, device,
diagnostic research.
The history of the inclusion of women in medical
research is really one of exclusion. In 1977 the FDA
banned the inclusion of women in clinical trials. To
a great extent this exclusion was motivated by the
thalidomide and DES tragedies. Although those
tragedies had nothing to do with clinical trials, they
had to do with harm to women, creating a feeling that
women should not be included in clinical trials. IThis
ban was meant to protect women and their fetuses, but
what it actually resulted in was an era of what we refer
to as the 'male norm' in clinical research. During that
era most research was done on young,
white, healths males. It became common
practice to extrapolate results from male
subjects to women. I do not think it will
come as any surprise that using the 'male
norm was not good for women's health.
In 1985 the United States Public lealth
Service determined that the lack of
information on women in clinical trials
was compromising women's health.
To address this, in 1986 the NIH urged
clinical researchers to include women in
their studies and to analyze the results by
sex. In 1990, with Congressional support,
the Society spearheaded a Government
Accountability Office (GAO) study. Ihe study found
that NIlH was failing to implement its own guidelines.
We knew NIH was not doing this, but we needed to
make it official. He asked Congress to investigate the
issue and discovered that NIl Iwas not following its
own mandate.1 That was the beginning of the Society
working with Congress to change lass.
There was not much progress at including women
in research until two events took place in 1993. The
first was the Revitalization Act, which required the
inclusion of women in all clinical research and analysis
of results by sex for Phase III trials. Second., the FDA
established guidelines for the study and evaluation of
gender differences in the clinical evaluation of drugs.2
Ihese guidelines did not encourage the inclusion of
women in safety and dosing studies, which are Phase I
and II., but required the inclusion of women in efficacy
trials, which are Phase Il
We worked with the GAO again in 2001 to investigate
what was being done at NTI and how much progress
was being made. The investigation revealed a few
things. Ihe audit of the FD A records revealed that the
IFDA had not etfectively oxverseen presentation and
analysis ot data related to sex ditterences and drug
development In fact, there wxere a number of dnigs
that had been taken off the market aftei it xxas shown
that they dispiroportionately caused adsverse reactions
in wxomnen. The analy sis shoxxed that 30 percent of
study documents failed to fulfill requirements for
presentation of outcome data by sex. Nearly 40 percent did not include
the required demographic information, demonstrating that the FDA had not
effectively overseen the presentation and analysis of data. He believe that
if the FDA had studied sex differences either the drugs would have stayed
on the market, women would have been monitored. or the drugs would not
have been prescribed for women.
In 2001 the board of directors of the Society decided that rather than just
looking at conditions that differently, disproportionately, and exclusively
attected women and inclusion in clinical trials, we should go more to the
basic level and see if we could validate the concept of research looking
into sex differences. At first we were not taken seriously. There we were,
a group of women, telling researchers and doctors that they were doing
research the wrong way and that some of the care they were providing
was not appropriate for women. Then we went to the Institute of Medicine
to convince them that this was an important study.' Ihis process took a
number of years, in part because we had to raise additional funds. In 2001,
we released our report entitled Exploring the Biological Contributions
to Human Health: Does Sex Matter? The report concluded that sex does
matter. It matters in health and disease from "womb to tomb " It emphasized
the need to carefully evaluate sex differences in medical research and
incorporate those differences into clinical practice. Biological sex needs to
be considered as a variable at all levels of research.
Ihe inclusion of women in clinical research and the fact that scientists
have begun finding differences between men and women in terms of
susceptibility, prevalence, time of onset, severits, and response to treatment
of various diseases and conditions, has led us to redefine women's health.
Today's definition of women's health moves beyond the reproductive
system and encompasses every disease and condition that affects women
disproportionately or differently. Biological sex differences result from
a combination of genetic, hormonal, physiological, and environmental
factors. These differences have real world consequences for the diagnosis
and treatment of diseases.
First let us look at heart disease. It was not until the Society had their first
Sex Differences Conference on cardiovascular disease that anyone really
started thinking that cardiovascular disease affects women. Heart disease
kills 500,000 American women each year. over 50,000 more women than
men, and strikes women, on the average. 10 years later. Women are more
likely than men to have a second heart attack within a year after the first
one. No one knows why. WHe do know there are significant sex differences
in the anatomy and phy siology of the heart and how heart disease manifests
itself.
Another example of sex differences arises wxith neur ological disordcirs.
We hasve alwsasys knoswn that men and wxomen's brains are different.
structurally and functionally. This inns result from the effects of estirogen
and testosterone during brain desvelopment and differences in response
to steroid hormones in localized regions of the brain later in life. These
differences can result in differino rates of certain neurological disorders mn
men and women.Cl For exanmple, womenCI Ihave higher ratcs of depressioni ad
anxiety disorders wxhile men hasve higher rates ot autism and AI)ID.
The list goes on. In almost every category of disease autoimmune, bone
diseases, etc.-there are differences betsxeen men and women. While science
has made great strides in understanding the basic biological differences,
there is still a great deal to learn. e have reached a crossroads at which we
need to examine how medical research is conducted and support programs
and policies to promote the study of biological sex diflferences. He have
spent more than a decade trying to raise awareness of the importance of
sex differences in health and disease among research scientists, clinicians,
funders, legislators, and the public. We have put together expert panels on
various topics, published reports, and funded four interdisciplinary research
networks. These four networks look at sex differences in cardiovascular,
metabolic, neurological, and musculoskeletal diseases.
About two and a half years ago we launched a new scientific membership
organization, the International Organization for the Study of Sex
Differences, which brings together scientists to look at sex differences. He
still face a lot of barriers. While there are a growing number of investigators
doing research on sex differences and the literature is expanding, many
scientists are still unaware that sex differences exist at every level. There
are no consistent efforts ansong the NIH to encourage studies that elucidate
sex differences of the basic biological mechanisms underlining these
differences. By requiring that all grant proposals include plans for data by
sex, the NIlI could ensure that sex difference becomes a de facto priority
in medical research. When the NIlH interpreted the 1993 legislation, they
interpreted it to require that women be included only in Phase III. He
believe that inclusion needs to occur in Phase I and II, looking at toxicity
and dosages.
There is also a problem in terms of the medical research. Scientific and
medical journals do not require that authors report the sex of their studies'
subjects, human or animal, or that results are analyzed by sex. As a
result many published studies do not contribute to our knowledge of sex
differences. IT all scientific journals required analysis by sex, researchers
would have to design their studies to detect sex differences. He believe
that funders and institutional review boards should require that all research
include women at all phases. Analysis of sex difflerences is not done
routinely and in some cases the number of fenale participants is too small
to obtain statistically significant data.
The 2007 review of published data from cardiovascular disease trials
shows that, of the 628 reviewed studies, three-quarters did not include sex
difference analysis, torty-one trials did not provide the sex ot participants,
and seventeen did not include women at all. At the basic research level,
studies on animal models do not routinely include both sexes as subjects.
We hasve been told that female animals are more expensive and more
complicated. but that does not mean thes should not be used,
Barriers to progress also exist at Use health care prosvider lesvel. P~hysicins
need to be informsed about sex differences to treat their patieints etfectisvely.
In 2005 an Amserican IHeart Association national study of physician
assareness showsed that phy sicians remain largely sunaxware ot sex differences
in caidioxvascular disease. Only eight percent of pimaiy caie phy sicians,
thirteen percent of OBGN 's, and sexventeen percent of cardiologists wverc
aw~xare that heart disease kills more xxwmen than men ever y~ ear.
Currently howv sex affects health and disease is notpart of nursing aind nmedical
school curriculum. it is important that health care providers be trained in
sex differences so they can appropriately evaluate, treat, and educate their
patients. Similarly, continuing medical education does not always include
research that looks at sex differences. Ihere is still physician bias. Female
and male patients showing up at a clinic with the same symptoms may
be treated differentl. Doctors often fail to recognize women's risks for
conditions such as heart disease, lung cancer,. and osteoarthritis. Even when
a physician diagnoses a condition such as heart disease, he or she is less
likely to refer a female patient to diagnostics and treatment. Wnxomen get
less aggressive treatment. Two alarming studies showed that even when
male and female patients had the exact same conditions and symptoms the
physicians' diagnoses were more aggressive for men.
Educating women about the importance of participation in clinical trials
is another area that we continue to work in and fund. The only time we
ever hear about clinical trials is when something goes wrong and it is on
the front page of the paper. If our goal is to learn what works better in
women and men, or children, or the elderly, or minorities, we need diverse
participation in clinical trials. We need to educate women and physicians.
Often physicians discourage people, both men and women, from entering
clinical trials.
In a nine-year cardiovascular disease study. which asked women what
is the greatest health problem facing women today, only eight percent
identified heart disease. The number went up to thirteen percent in 2003
and twenty-one percent in 2006. WN omen fear breast cancer more than
heart disease, but in reality they are much more vulnerable to heart disease
and in many respects it is preventable. Ihere are problems with how the
media interprets scientific data fron the published literature and reports
study findings incorrectly. Ihis contributes to patient confusion and lack
of confidence. One example of this that is still controversial is the way in
which the Women's IHealth Initiative (WIII) study was halted. We believe it
is a perfect example of miscommunication leading to confusion. IThe WIII
was a federallx funded study to determine whether hormone replacement
therapx reduces the risk of heart disease in post-menopausal women. Since
the release of the initial results, contradictory information has come to light.
Women are still confused as to whether hormone therapy is safe, whether
taking calcium helps their bones, and whether low fat diets are beneficial
for their health.
We are faced with a system where in many respects patients are forced to
be their own health advocates as consumers in a complicated health care
system. This works for onlx a fraction of educated consumers. For the
majority of us it is extremely difficult enough to figure out the health care
system, much less to develop a relationship with a provider. If a patient asks
too many questions or appears to question the authority of the phy sician,
the patient is often labeled as difficult.
Research teams need to think broadly about research questions, including
sex as a xvariable in both basic and clinical research and iequiring analxysis
ax reporting results bx sex. Journals also need to report bx sex. Sometimes
xvhen an article is too long a journal wxill cut out the portion haxving to do
xxith wxomen or xxill simply refer to wxomen as 'patients'. Often readers do
nut know x whether xwomexn xxerc included. Imnagine. youu are a cardiologist
reading an article in the popular journal. Circulation, about a major trial
Blood and tissue samples that are stored in repositories should indicate the
sex and hormonal status of the donor. For women, this would include pre-
pubescent, reproductive, pregnant, menopause, post-menopause statuses.
As the Institutes of Medicine suggest, research needs to be conducted in
individuals from womb to tomb. We need faster translation of basic research
results into the clinic, not just in terms of better drugs and diagnostics, but
in the adoption of new technologies that are affordable. We need to develop
guidelines to educate providers on how sex differences impact the health
and health care of women.
In closing we believe that the study of sex differences is the strongest
approach to improve wonen's health. As sex differences research evolves
and is translated into more personalized medical treatments, both sexes will
equally benefit. Understanding the difterences in how diseases manifest
themselves in women also helps us understand the mechanism in men. We
will all equally benefit from better health and health care.
Corrine Parver:
If you were to emphasize to policymakers that sex differences research
benefits both men and women. rather than just women, would they be more
responsive to the issue?
Phyllis Greenberger:
For many years we have been trying to convince the pharmaceutical
industry that if they do not do testing on women in the early stages of drug
development, we will find problems once the drugs are on the market. The
industry would rather have a drug that is out there for everybody and worry
about problems later, than spend more time and money doing complicated
and costly trials that will only allow them to market the drug to half the
population. Obtaining funds from Capitol 1Hill is a long shot. It is up to the
NlIH directors. Some NIlHI directors get it and are doing the right thing, but
the majority of them do not.
We did a study a number of years ago looking at the percentage of proposals
that were funded by the NIH1. At that time only three percent related to sex
difference research. Ihe institutes that one would think xwould have more
of a focus on women's issues, such as the Cancer Institute and the Heart
-Lung and Blood Institute, were the worst. Nobody is against knowing what
works best and there are a lot of things that could be improved. We are still
learning about sex differences in diagnostics. devices, and pharmaceuticals.
WXe are concerned that if the NIH starts looking at comparative effectiveness
without taking into consideration sex differences we may end up
backtrackino from the progress xxe haxve made so far.
on cardiovascular disease, but the article only refers to males. Ihen there
might be in a smaller journal, less popular among healthcare providers, in
which the part on wonen is included.
